| Literature DB >> 25887273 |
Konstantina Dimitrakopoulou1, Aristidis G Vrahatis2,3, Anastasios Bezerianos4,5.
Abstract
BACKGROUND: The avalanche of integromics and panomics approaches shifted the deciphering of aging mechanisms from single molecular entities to communities of them. In this orientation, we explore the cardiac aging mechanisms - risk factor for multiple cardiovascular diseases - by capturing the micronome synergism and detecting longevity signatures in the form of communities (modules). For this, we developed a meta-analysis scheme that integrates transcriptome expression data from multiple cardiac-specific independent studies in mouse and human along with proteome and micronome interaction data in the form of multiple independent weighted networks. Modularization of each weighted network produced modules, which in turn were further analyzed so as to define consensus modules across datasets that change substantially during lifespan. Also, we established a metric that determines - from the modular perspective - the synergism of microRNA-microRNA interactions as defined by significantly functionally associated targets.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25887273 PMCID: PMC4367845 DOI: 10.1186/s12864-015-1256-3
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Methodology workflow for detecting integromics modules. A. Construction of the miRNA-mRNA multi-layer regulatory network based on interaction databases and hypergeometric distribution (in case of miRNA-miRNA relations). B. Two adapted weighting schemes were employed to integrate the mRNA/miRNA expression information onto the corresponding network layer so as to create the integromics network. C. The integromics network was the input to the DMSP module-detecting algorithm and statistically significant modules (P-value < 0.05) were identified based on a permutation strategy on the expression data.
Figure 2Degree distribution, weight distribution and topological analysis. A) Degree distribution of nodes (mRNAs/miRNAs); blue refers to the complete set and red to the fraction of nodes included in the consensus modules. The variance of modular nodes was significantly different (Bartlett test, P-value = 1.4E-39) and with higher mean value, which is translated into more hub nodes favored during module construction. B) Calculation of the characteristic path length (CPL) of the complete network, of the network after removing the 186 age-dependent nodes, of the network after removing the 429 consensus modular nodes, of the network after removing the top 429 hub nodes and of the network after removing randomly 429 nodes (mean value after 100 runs). If the nodes removed are important mediators for network communication CPL will increase. C) Weight distribution of the complete multi-layer network with bars representing the mean edge weight value as calculated from all combinations of mRNA/miRNA expression experiments and error bars depicting the confidence intervals. Each bar represents a value range named after the upper limit. All weight values were adjusted to ‘1-weight value’ due to the fact that DMSP algorithm constructs modules by promoting edges with weights closer to zero. As shown, with cutoff value ≤ 0.4, only 8% of the complete interactome (~5,300 edges) changed substantially during lifespan D) Weight distribution of the edges included in the final consensus modular topology. With cutoff value ≤ 0.4, 1,270 edges were included in the consensus modular topology which represent the 24% of the total age-related relations (one-sided Fisher exact test, P-value = 2.2E-16).
miRNA synergism results relative to consensus modules
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| miR-125a-5p | miR-351 | 5 | Various cancer types | [ | ||
| miR-200c | miR-429 | 10 | Various cancer types | Various cancer types | [ | [ |
| miR-125b-5p | miR-351 | 112 | Cardiac hypertrophy | [ | [ | |
| miR-15b | miR-195 | 174 | Cardiac hypertrophy | Cardiac hypertrophy/heart failure | [ | |
| miR-148a |
| 194 | Various diseases | Various diseases | [ | |
| miR-200b | miR-200c | 199 | Various cancer types | Various cancer types | [ | [ |
| miR-132 | miR-190b | 221 | Various diseases | [ | ||
| miR-190b | miR-465a-5p | 261 | ||||
| miR-190b | miR-692 | 309 | ||||
| miR-107 | miR-15b | 327 | Cardiac hypertrophy | Cardiac hypertrophy | [ | |
|
| miR-195 | 342 | Various diseases | Cardiac hypertrophy/heart failure | [ | |
| miR-148b |
| 353 | Various diseases | Various diseases | [ | |
| miR-132 | miR-429 | 371 | Various diseases | Various cancer types | [ | |
| miR-130b | miR-301a | 372 | Various cancer types | [ | ||
|
| miR-135b | 395 | Various cancer types | Various cancer types | [ | |
| miR-101a | miR-101b | 396 | Various cancer types | |||
| miR-147 | miR-148a | 397 | Various cancer types | Various diseases | [ | |
| miR-125a-5p | miR-125b-5p | 400 | Various cancer types | Cardiac hypertrophy | [ | |
| miR-133a | miR-133b | 401 | Cardiac hypertrophy/cardiomyopathy/myocardial infarction | Myocardial infarction | [ | [ |
| miR-103 | miR-107 | 407 | Cardiac hypertrophy | Cardiac hypertrophy | ||
| miR-141 | miR-200a | 408 | Various cancer types | Various cancer types | [ | [ |
| miR-147 | miR-148b | 410 | Various cancer types | Various diseases | ||
| miR-200a | miR-200b | 412 | Various cancer types | Various cancer types | [ | [ |
| miR-141 | miR-200b | 413 | Various cancer types | Various cancer types | [ | [ |
| miR-148a | miR-148b | 415 | Various diseases | Various diseases | ||
| miR-200b | miR-204 | 427 | Various cancer types | Various cancer types | [ | |
| miR-141 | miR-200c | 464 | Various cancer types | Various cancer types | [ | [ |
| miR-26a | miR-26b | 465 | Cardiac hypertrophy | Cardiac hypertrophy | [ | |
| miR-23a | miR-23b | 493 | Cardiac hypertrophy | Cardiac hypertrophy | ||
|
| miR-200a | 494 | Various cancer types | Various cancer types | [ | [ |
| miR-204 | miR-211 | 537 | Various cancer types | Various cancer types |
miRNA synergism results for the consensus modules according to Borda voting scheme. Each line reports the Borda rank of each miRNA pair identified in the final consensus modules, disease-related information of the human orthologs as recorded in miR2Disease database (if found only cardiac pathophysiology related terms are reported) and evidence related to aging or cardiac pathophysiology provided by recent literature. We denote that in many cases each member of the reported miRNA pair can participate in a different module. Bold miRNAs are age-dependent based on linear regression analysis.
miRNA synergism results beyond consensus modules
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
|
| 1 | Various diseases | Various diseases | [ | [ |
|
|
| 2 | Various cancer types | Various cancer types | [ | [ |
|
|
|
| Alzheimers disease | Lupus nephritis | ||
| miR-181b | miR-181d | 4 | Cardiac hypertrophy | Various diseases | ||
|
|
| 6 | Various cancer types | Various cancer types | [ | |
| miR-18a | miR-18b | 7 | Various cancer types | Cardiac hypertrophy | [ | |
| miR-128 |
| 8 | Various diseases | Cardiac hypertrophy | ||
|
| miR-291a-3p | 9 | Various diseases | [ | ||
| miR-30a | miR-30e | 100 | Cardiac hypertrophy | Cardiac hypertrophy | [ | [ |
| miR-30e | miR-384-5p | 132 | Cardiac hypertrophy | [ | [ | |
| miR-30c | miR-30e | 184 | Cardiac hypertrophy | Cardiac hypertrophy | [ | [ |
| miR-294 | miR-30e | 318 | Cardiac hypertrophy | [ | ||
| miR-291a-3p | miR-30e | 364 | Cardiac hypertrophy | [ | ||
| miR-18b | miR-297c | 385 | Cardiac hypertrophy | |||
| miR-190 | miR-194 | 391 | Various cancer types | Cardiac hypertrophy | [ | |
| miR-30d | miR-30e | 398 | Cardiac hypertrophy | Cardiac hypertrophy | [ | |
|
|
| 399 | Various diseases | Various cancer types | [ | |
| miR-30e | miR-495 | 411 | Cardiac hypertrophy | Various diseases | [ | [ |
| miR-139-3p | miR-150 | 438 | Cardiac hypertrophy | Cardiac hypertrophy | [ | |
| miR-30e |
| 453 | Cardiac hypertrophy | [ | ||
| miR-1 | miR-18a | 457 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Various cancer types | [ | [ |
| miR-187 | miR-18b | 460 | Non-alcoholic fatty liver disease (NAFLD) | Cardiac hypertrophy | ||
| miR-185 | miR-18b | 462 | Cardiac hypertrophy | Cardiac hypertrophy | ||
| miR-100 | miR-30e | 489 | Various diseases | Cardiac hypertrophy | [ | [ |
| miR-1 |
| 492 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Various cancer types | [ | [ |
| miR-1 | miR-206 | 512 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Various diseases | [ | |
| miR-194 | miR-210 | 530 | Cardiac hypertrophy | Various diseases | [ | [ |
| miR-192 | miR-218 | 548 | Various cancer types | Cardiac hypertrophy | [ | |
| miR-191 | miR-218 | 549 | Various cancer types | Cardiac hypertrophy | [ | |
| miR-18b | miR-219 | 550 | Cardiac hypertrophy | Various cancer types | ||
| miR-18b | miR-22 | 552 | Cardiac hypertrophy | Various diseases | [ | |
|
|
| 563 | Various diseases | Various cancer types | [ | |
| miR-150 | miR-224 | 570 | Cardiac hypertrophy | Various cancer types | [ | |
| miR-18b | miR-297b-5p | 599 | Cardiac hypertrophy | |||
| miR-150 | miR-296-5p | 620 | Cardiac hypertrophy | Various diseases | [ | |
| miR-1 |
| 634 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Cardiac hypertrophy | [ | [ |
| miR-1 | miR-29b | 636 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Cardiac hypertrophy | [ | [ |
| miR-1 | miR-29c | 639 | Cardiac hypertrophy/cardiomyopathy/heart failure/myocardial infarction/coronary artery disease | Cardiac hypertrophy | [ | [ |
Synergism results for miRNA pairs that ranked in the upper quartile according to Borda voting scheme but not incorporated in the consensus modules (indicative examples). Each line reports the rank of each miRNA pair, disease-related information of the human orthologs as recorded in miR2Disease database (if found only cardiac pathophysiology related terms are reported) and evidence related to aging or cardiac pathophysiology provided by recent literature. Bold miRNAs are age-dependent based on linear regression analysis. We also added miRNA pairs with high rank yet not related to aging or cardiac pathophysiology (highlighted in italics).
Figure 3miRNA-miRNA synergistic network. This network incorporates the miRNA relations that ranked in the upper quartile (639 edges) of the Borda voting scheme. Blue colored nodes represent miRNAs involved in mouse consensus modules. Edges with larger width highlight the relations included in consensus modules. Red colored nodes represent age-dependent miRNAs as estimated by linear regression analysis. Red colored miRNAs with blue border are both age-dependent and participate in consensus modules. Nodes with orange colored border represent miRNAs associated to human cardiac pathophysiology as reported in miR2Disease database. Purple edges highlight the 10 top scoring miRNA relations.
Figure 4Mouse consensus modules. Layout of the 40 consensus modules. The topology includes 3,780 edges among 38 miRNAs and 391 proteins. The multi-layer modules are visualized in two levels, i.e. micronome and proteome. Nodes in many cases are multi-colored (with the use of ExprEssence Cytoscape plug-in by Warsow et al. [53]) in a pie-chart-like form so as to visualize the participation of a node in multiple modules. Blue dotted edges highlight miRNA relations not included into consensus modules yet exhibited significant synergy.
Analysis of mouse consensus modules
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | 18 | One-carbon metabolic process | 11.8 | 5.0E-2 | N/A | N/A | N/A |
| 2 | 22 | Cellular aromatic compound metabolic process | 10 | 5.0E-2 | N/A | GOS2 | |
| 3 | 5 | N/A | N/A | N/A | N/A | N/A | |
| 4 | 9 | N/A | N/A | N/A | miR-34a | N/A | N/A |
| 5 | 68 | Generation of precursor metabolites and energy | 73.5 | 1.6E-77 | N/A | HADH, NDUFA10, NDUFV1 | SLC25A4, UCP2 |
| 6 | 23 | N/A | N/A | N/A | N/A | CDH22 | N/A |
| 7 | 4 | N/A | N/A | N/A | N/A | N/A | N/A |
| 8 | 5 | Heart development | 40 | 5.0E-2 | N/A | N/A | N/A |
| 9 | 8 | N/A | N/A | N/A | N/A | NDUFA10 | N/A |
| 10 | 16 | Tissue development | 30.8 | 7.2E-3 | N/A | N/A | EPS8 |
| 11 | 20 | N/A | N/A | N/A | N/A | N/A | BUB1B |
| 12 | 27 | N/A | N/A | N/A | N/A | N/A | BUB1B, MCM2 |
| 13 | 24 | N/A | N/A | N/A | N/A | RHOU | N/A |
| 14 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 15 | 6 | N/A | N/A | N/A | miR-466d-3p | IER3 | N/A |
| 16 | 8 | N/A | N/A | N/A | N/A | N/A | N/A |
| 17 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 18 | 13 | N/A | N/A | N/A | miR-152 | N/A | N/A |
| 19 | 36 | N/A | N/A | N/A | N/A | RPL10, RPL37 | N/A |
| 20 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 21 | 13 | N/A | N/A | N/A | N/A | N/A | N/A |
| 22 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 23 | 13 | Response to DNA damage stimulus | 53.8 | 1.4E-8 | N/A | N/A | ERCC2 |
| 24 | 8 | N/A | N/A | N/A | N/A | N/A | MCM2 |
| 25 | 6 | N/A | N/A | N/A | N/A | RPA3 | N/A |
| 26 | 6 | N/A | N/A | N/A | N/A | N/A | N/A |
| 27 | 7 | N/A | N/A | N/A | N/A | N/A | N/A |
| 28 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 29 | 7 | N/A | N/A | N/A | N/A | EEF2 | N/A |
| 30 | 8 | N/A | N/A | N/A | N/A | N/A | N/A |
| 31 | 6 | N/A | N/A | N/A | N/A | N/A | N/A |
| 32 | 5 | N/A | N/A | N/A | N/A | N/A | N/A |
| 33 | 6 | N/A | N/A | N/A | miR-135a | N/A | N/A |
| 34 | 4 | N/A | N/A | N/A | N/A | N/A | N/A |
| 35 | 28 | Cellular nitrogen compound metabolic process | 78.6 | 6.2E-12 | N/A | N/A | N/A |
| 36 | 25 | Cellular nitrogen compound metabolic process | 76 | 2.1E-9 | N/A | N/A | N/A |
| 37 | 8 | N/A | N/A | N/A | N/A | N/A | N/A |
| 38 | 24 | N/A | N/A | N/A | N/A | N/A | N/A |
| 39 | 10 | N/A | N/A | N/A | N/A | N/A | MCM2 |
| 40 | 10 | N/A | N/A | N/A | N/A | N/A | N/A |
Summary of the 40 consensus modules. Count: The number of module members; Gene Ontology (GO) term: Statistically significant GO terms based on DAVID tool (P-value <= 0.05); Percentage: The percentage of modular genes characterized by the specific GO term; Fisher exact P-value: modified Fisher exact P-value (EASE score) as provided by DAVID (the complete mouse genome was used as background); Age-dependent miRNAs: Age-dependent miRNAs based on linear regression analysis; Age-dependent genes: Age-dependent genes based on linear regression analysis; GeneAge genes: longevity-associated genes according to GenAge database. N/A: not available.
Figure 5Homology-based human modules. Layout of the three human modules descending after the homology-based matching between human and mouse consensus modules. Module A displayed significant node overlap relative to mouse Mod_5, module B to Mod_13 and module C to Mod_19. Pink nodes highlight the homologs.
Disease annotation data for proteins included in human modules
|
|
|
|
|---|---|---|
| NDUFS2 | NADH dehydrogenase Fe-S protein 2 | Cardiomyopathies |
| NDUFV2 | NADH dehydrogenase flavoprotein 2 | Cardiomyopathies |
| ARHGAP9 | Rho GTPase activating protein 9 | Coronary Vasospasm |
| HADHB | hydroxyacyl-CoA dehydrogenase | Heart Diseases |
| ATP5J | ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 | Heart Diseases |
| ARHGDIB | Rho GDP dissociation inhibitor (GDI) beta | Acute Coronary Syndrome |
| RHOJ | ras homolog family member J | Cardiomyopathies |
| NDUFS1 | NADH dehydrogenase Fe-S protein 1 | Cardiomyopathy, Hypertrophic |
| UCP3 | uncoupling protein 3 | Heart Failure/Hypertrophy, Right Ventricular |
| ATP5I | ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E | Heart Diseases |
| COX5B | cytochrome c oxidase subunit Vb | Myocardial Ischemia/Cardiomegaly |
| NDUFA2 | NADH dehydrogenase 1 alpha subcomplex, 2 | Coronary Disease |
| NDUFB3 | NADH dehydrogenase 1 beta subcomplex, 3 | Coronary Disease |
Cardiovascular disease annotation data for 13 proteins participating in the human modules. Data was obtained from DisGeNET database.
Age-dependent mRNAs/miRNAs
|
|
|
|---|---|
| miR-106a | 1810046J19RIK, 2310044G17RIK, 2900073G15RIK, ACOT1, AKR1C13, |
|
| ALAS1, ALDOB, AMPD3, AMY1, ANKRD1, ANXA5, AOX1, APBB1, BAIAP2L1, BAX, BLCAP, C1QA, C3, CAT, CCND1, CCNDBP1, CDC37, CDC37L1, |
| miR-142-3p | |
| miR-146b | |
|
| |
| miR-199a-5p | |
| miR-19a | |
| miR-19b | |
| miR-21 | |
| miR-221 | |
| miR-222 | |
| miR-223 | |
| miR-27b | |
| miR-290-5p | |
| miR-29a | |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
Using a linear regression model and two-tailed F-test, 24 age-dependent miRNAs and 162 age-dependent mRNAs were identified (P-value < 0.05). Bold indicates miRNAs and mRNAs included in the consensus modules. Italics indicate miRNAs with insignificant synergistic effect.
Figure 6Estimation of miRNA synergy. Example illustration for calculating Inter miRNA synergy for miRNA pairs not included in the same module. Suppose miRNA A targets modules A, B, C, D and miRNA B targets modules E and F. There are 8 possible pairs AE, AF, BE, BF, CE, CF, DE and DF to be examined for shared edges between modules and the number of union proteins. In this example the Inter score was estimated to 0.29.